ArriVent BioPharma (AVBP) is a pre-revenue clinical-stage biopharma with no tangible operating assets beyond cash and short-term investments. Under a liquidation lens as of December 31, 2025, the recovery picture is dominated almost entirely by liquid financial assets on the asset side, set against a modest current liability stack and zero long-term financial debt drawn. Total assets are $333.2M, of which $332.9M are current. Cash and cash equivalents are $45.5M (100% recovery), short-term investments (available-for-sale debt securities) are $267.3M (recovery estimated at ~99-100% given Level 1/2 fair value marks and <12-month maturity profile), and prepaid/other current assets of $20.1M (effectively zero recovery on clinical prepayments in wind-down). Total current liabilities are $25.9M, all current, consisting of accounts payable ($5.9M), accrued liabilities ($20.0M including $6.5M employee-related and $13.3M clinical/other accruals), and a de minimis operating lease liability ($14K). No funded debt is outstanding; the $75M SVB term loan facility was undrawn at period end. Applying standard haircuts: cash + investments recoverable at roughly $312M, less $25.9M in face-value liabilities, yields approximate equity recovery in the range of $285-290M against reported book equity of $307.2M. The gap between book equity and estimated liquidation recovery is driven primarily by (1) the $20.1M in prepaid and other current assets receiving a near-zero haircut (clinical commitments with CROs/CMOs are largely non-recoverable on wind-down per the filing's disclosure that purchase orders for clinical materials are generally non-cancellable), and (2) the $0.2M ROU asset receiving zero recovery. Material off-balance-sheet contingent obligations include up to $105M in clinical/regulatory milestones and $655M in commercial milestones under the Allist agreement, up to $201.5M development milestones and $414M commercial milestones under Alphamab, and up to $300M development and $890M commercial milestones under Lepu — all contingent and not triggered; none are accrued liabilities on the balance sheet. The Lepu $40M upfront and Allist $5M milestone paid in 2025 have been fully expensed. The valuation allowance against $109.3M in gross deferred tax assets increased by $40.4M in 2025; no deferred tax assets are recoverable in liquidation. The $37.6M in unrecognized stock compensation cost is a forward income statement item only. Compared to the prior 10-Q (9/30/2025), the year-end balance reflects the Q4 burn of approximately $28.8M net cash decrease, consistent with the annual operating cash outflow of $160.6M. The asset base improved modestly via the Q4 completion of ATM sales (full-year ATM proceeds of $122.2M net plus $80.5M July offering). Accrued liabilities grew from $13.3M (12/31/2024) to $20.0M (12/31/2025), reflecting expanded CRO/CMO accruals as clinical programs scaled. No new debt or lease obligations were added that would shift the liquidation posture materially. The filing does not separately XBRL-tag the contingent milestone obligations in a balance-sheet line; they appear only in narrative Note 11.
▼ Community Notes